The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | AUGMENT-ing treatment: lenalidomide plus rituximab for R/R indolent NHL
John Leonard, MD, from Weill Cornell Medical College, New York City, NY, discusses the Phase III AUGMENT study (NCT01938001) comparing the use of lenalidomide plus rituximab (R2) vs. rituximab and a placebo in relapsed/refractory indolent non-Hodgkin lymphoma (follicular lymphoma and marginal zone lymphoma). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Leonard reveals that despite additional toxicity, R2 demonstrated superior efficacy over the rituximab arm and provides an important new treatment option in this patient group, with meaningful advantages over single-agent rituximab.
